CompletedNCT01593774
Melatonin to Study Metabolic Side Effects of Olanzapine
About this title
Read the official source — NCT01593774Medication studyAges 18–65IranSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- RashtSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 36
- Sponsor
- Guilan University of Medical Sciences
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Iran
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01593774
- Official title
Show the full official title
Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Rasht
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Guilan University of Medical Sciences, a university.
Did this study involve medication?
Yes. The study involved medication, including Melatonin and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
